

1    **Supplementary Material: Autoantibodies in COVID-19 correlate**  
2    **with anti-viral humoral responses and distinct immune signatures**

3

4    **Supplementary Figures**

5    **Figure S1. ANA patterns in healthy controls and COVID-19 patients during acute disease**  
6    **and follow-up.** (A–D) Intersection plots showing the counts of all ANA patterns (horizontal  
7    bars) and counts of pattern combinations (vertical bars) as indicated by the dot matrix, as  
8    observed in healthy individuals (A; n = 41), acute COVID-19 patients (B; n = 175), and  
9    COVID-19 patients six months (C; n = 116) and one year (D; n = 92) after recovery.

10

11    **Figure S2. S1-specific humoral response in ANA-positive and ANA-negative COVID-19**  
12    **patients one year after recovery.** S1-specific IgA and IgG in ANA-positive and ANA-  
13    negative COVID-19 patients (n = 37).

14


15    **Figure S3. Human virome-wide serological profiling in healthy controls and acute**  
16    **COVID-19 patients.** (A) Percentage of healthy controls (n = 18) and COVID-19 patients (n =  
17    97) with positive results for all available epitopes of six coronavirus species. Significantly  
18    enriched epitopes ( $p < 0.05$ ) are colored and shaped according to the corresponding protein.  
19    Dashed lines indicate significance threshold ( $p < 0.05$ ). (B) Summed epitope hits of EBNA-2  
20    and correlation with age in in ANA-negative and -positive participants (n = 115).

21


22 **Figure S4. Multivariate characterization of ANCA-positive and ANCA-negative acute**  
23 **COVID-19 patients.** (A) PCA accounting for 130 parameters including data of healthy  
24 controls ( $n = 28$ ) and acute COVID-19 patients ( $n = 146$ ). Participants with missing values  
25 were excluded from this analysis. (B) Loadings (variable coordinates) of the PCA depicted in  
26 (A), with each parameter shown as an individual dot (**Table S5**). Colors indicate participant  
27 group with higher mean, and parameters with significant differences ( $p < 0.05$ ) comparing  
28 ANCA-positive and ANCA-negative COVID-19 patients are shown as large dots and  
29 annotated.

30


### A Healthy controls



### B Acute COVID-19



### C 6-month follow-up



### D 1-year follow-up




Figure S1\_Taeschler et al.





Figure S2\_Taeschler et al.

A



B




Figure S3\_Taeschler et al.




Figure S4\_Taeschler et al.

		COVID-19 1-year follow-up	
	Disease severity n (%)	Mild	Severe
<b>Patient characteristics</b>	<b>Age</b>	36 (31–52)	56 (36–69)
	<b>Days after symptom onset</b>	376 (366–387)	380 (367–396)
	<b>Sex (female)</b>	34 (53.1%)	8 (28.6%)
	<b>Vaccinated</b>	42 (65.6%)	13 (46.4%)
	<b>Hospitalized</b>	8 (12.5%)	28 (100%)
<b>Laboratory parameters</b>	<b>Lymphocyte count (G/l)</b>	1.94 (1.58–2.37)	1.89 (1.63–2.60)
	<b>CRP (mg/l)</b>	1 (0.6–2.5)	1.6 (0.7–3.0)
	<b>TNF-<math>\alpha</math> (ng/l)</b>	9.2 (7.6–11.3)	9.5 (7.5–11.6)
	<b>IL-6 (ng/l)</b>	1.2 (0.2–2.1)	1.8 (0.7–3)
	<b>S1-specific IgA (OD ratio)</b>	8.38 (3.9–10.0)	7.49 (3.24–8.59)
<b>Comorbidities</b>	<b>S1-specific IgG (OD ratio)</b>	10.0 (5.60–10.0)	9.29 (5.12–10.0)
	<b>Hypertension</b>	6 (9.4%)	15 (53.6%)
	<b>Diabetes</b>	3 (4.7%)	6 (21.4%)
	<b>Heart disease</b>	2 (3.1%)	9 (32.1%)
	<b>Lung disease</b>	5 (7.8%)	8 (28.6%)
	<b>Malignancy</b>	0	7 (25.0%)
	<b>Kidney disease</b>	3 (4.7%)	9 (32.1%)
	<b>Autoimmune disease</b>	6 (9.4%)	3 (10.7%)

**Table S1. Characteristics of COVID-19 patients at one year after infection.** For continuous variables, medians and interquartile ranges (in parentheses) are specified. Numbers of individuals (n) and percentages of the corresponding subgroup (in parentheses) are shown for categorical variables. OD, optical density.

		Vaccinated individuals without prior COVID-19		
Blood sampling timepoint		1–3 days before vaccination	11–13 days after first vaccination	1–3 days after second vaccination
Patient characteristics	n	11	11	10
	Age	29 (27–30)	29 (27–30)	29 (27–31)
	Sex (female)	5 (45.5%)	5 (45.5%)	4 (40%)
Laboratory parameters	ANA-positive	3 (27.3%)	6 (54.5%)	3 (30%)
	S1-specific IgA [OD ratio]	0.34 (0.3–0.5)	8.29 (7.73–8.43)****	3.33 (2.87–6.31)***
	S1-specific IgG [OD ratio]	0.12 (0.12–0.16)	5.92 (5.38–6.70)****	8.59 (8.10–9.79)***

**Table S2. Characteristics of vaccinated individuals before vaccination and after first and second vaccination with BNT162b2.** Medians and interquartile ranges (in brackets) are specified for continuous variables, with p-values obtained by Wilcoxon signed rank test compared to before vaccination. Numbers of individuals (n) and percentages of corresponding subgroup (in parentheses) are shown for categorical variables. \*\*\*, p < 0.001; \*\*\*\*, p < 0.0001; OD, optical density.

<b>S1 specific IgA (OD ratio, square root)</b>			
<b>Parameter</b>	<b>Estimate</b>	<b>95% CI</b>	<b>p-value</b>
Intercept	1.196	0.918–1.473	<b>&lt;0.0001</b>
Age [years]	0.008	0.002–0.014	<b>0.013</b>
Disease severity ( <i>severe</i> )	0.462	0.216–0.708	<b>0.00026</b>
Sampling timepoint ( <i>6 months</i> )	-0.017	-0.208–0.174	0.862
ANA ( <i>positive</i> )	0.122	-0.078–0.323	0.231
<b>S1 specific IgG (OD-ratio, square root)</b>			
<b>Parameter</b>	<b>Estimate</b>	<b>95% CI</b>	<b>p-value</b>
Intercept	0.689	0.403–0.976	<b>&lt;0.0001</b>
Age [years]	0.0068	0.0002–0.0134	<b>0.048</b>
Disease severity ( <i>severe</i> )	0.595	0.341–0.894	<b>&lt;0.0001</b>
Sampling timepoint ( <i>6 months</i> )	0.543	0.345–0.740	<b>&lt;0.0001</b>
ANA ( <i>positive</i> )	0.314	0.107–0.522	<b>0.0031</b>

**Table S3. Multiple linear regression for S1-specific IgA and IgG.** Analysis accounting for age (continuous; years), disease severity (categorical; mild or severe disease), sampling timepoint (categorical; acute or 6 months) and presence of ANA (categorical; negative or positive). All observations of unvaccinated COVID-19 patients during acute COVID-19 (n = 175) and 6 months after recovery (n = 104) were included in the analysis. OD, optical density.

Viral species	Average peptide hits	Mean fold change COVID-19 / healthy	p-value
Human herpesvirus 4	64.08	1.06	ns
Human herpesvirus 5	61.33	1.53	***
Human herpesvirus 1	46.38	1.14	ns
Orf virus	24.95	1.09	*
Human herpesvirus 2	24.94	1.22	ns
Influenza A virus	24.75	1.05	ns
Enterovirus B	22.43	0.53	***
Rhinovirus A	20.53	0.47	****
Human herpesvirus 3	17.86	1.09	ns
Enterovirus C	16.96	0.58	*
Molluscum contagiosum virus	16.70	1.09	*
Human respiratory syncytial virus	11.92	0.81	ns
Hepatitis B virus	11.89	1.97	ns
Hepatitis C virus	10.91	1.12	ns
Human coronavirus HKU1	10.54	1.14	ns
Human adenovirus C	10.11	0.98	ns
Human adenovirus B	9.18	1.10	ns
Chikungunya virus	8.45	1.11	ns
Pegivirus A	7.91	1.15	***
Rhinovirus B	6.82	0.43	****
Influenza B virus	6.33	0.57	ns
Human herpesvirus 8	6.10	1.03	ns
Rubella virus	5.76	1.20	ns
Human immunodeficiency virus 1	5.75	1.52	ns
Hepatitis E virus	5.73	1.27	ns
Middle East respiratory syndrome coronavirus	5.52	1.78	***
Human herpesvirus 6A	5.04	1.05	ns
Dengue virus	4.84	2.34	*
Enterovirus A	4.33	0.51	*
Human adenovirus D	4.24	1.13	ns
Alphapapillomavirus 3	4.19	0.95	ns
Cowpox virus	4.09	1.04	ns
Human adenovirus E	4.03	1.16	ns
Venezuelan equine encephalitis virus	3.65	1.13	ns
Human herpesvirus 6B	3.64	0.97	ns
Ross River virus	3.48	0.99	ns
Betapapillomavirus 1	3.25	1.01	ns
Human adenovirus F	3.16	1.06	ns
Sudan ebolavirus	2.99	1.09	ns
Zaire ebolavirus	2.95	1.21	ns
Alphapapillomavirus 2	2.70	1.16	ns
Human adenovirus A	2.66	1.13	ns
Merkel cell polyomavirus	2.65	0.92	ns
Mamastrovirus 1	2.58	1.26	ns
Alphapapillomavirus 6	2.17	0.97	ns
Influenza C virus	2.15	0.59	ns
Alphapapillomavirus 4	2.05	1.03	ns
Bundibugyo ebolavirus	2.04	1.06	ns
Adeno-associated dependoparvovirus A	2.01	1.20	ns
Sapporo virus	1.98	0.82	ns
Yellow fever virus	1.96	1.43	ns
Cosavirus A	1.94	1.19	ns
Torque teno virus	1.91	0.95	ns
Severe acute respiratory syndrome-related coronavirus	1.90	7.95	****
Rotavirus A	1.89	1.74	ns
Variola virus	1.87	1.10	ns
Human herpesvirus 7	1.82	0.45	*
Vaccinia virus	1.65	0.99	ns
Alphapapillomavirus 10	1.61	1.09	ns
Colorado tick fever virus	1.59	1.23	ns
O'nyong-nyong virus	1.57	1.34	*

Eastern equine encephalitis virus	1.56	0.82	ns
Norwalk virus	1.55	0.66	ns
Alphapapillomavirus 7	1.48	1.19	ns
Alphapapillomavirus 9	1.42	1.41	ns
Human parvovirus B19	1.34	0.44	ns
Powassan virus	1.32	0.89	ns
Pseudocowpox virus	1.28	1.12	ns
Betapapillomavirus 2	1.27	2.83	ns
Louping ill virus	1.26	1.10	ns
Human immunodeficiency virus 2	1.25	0.93	ns
Betacoronavirus 1	1.25	2.48	*
Rosavirus A	1.24	1.07	ns
Hepatitis delta virus	1.18	1.92	ns
Sindbis virus	1.18	1.08	ns
Measles virus	1.12	0.77	ns
Tanapox virus	1.04	1.20	ns
Hepatitis A virus	0.96	3.22	ns
Salivirus A	0.82	1.41	ns
Human coronavirus 229E	0.76	3.89	*
Human coronavirus NL63	0.76	2.14	ns
Aichivirus A	0.67	1.40	ns
Enterovirus D	0.67	0.36	***
Yaba monkey tumor virus	0.65	2.59	ns
Dugbe virus	0.60	1.63	ns
Human parainfluenza virus 3	0.60	0.48	ns
Lassa virus	0.58	2.29	ns
Reston ebolavirus	0.55	1.29	ns
Human metapneumovirus	0.54	0.87	ns
West Nile virus	0.53	11.06	*
Rabies virus	0.51	0.49	ns
Human parainfluenza virus 4	0.45	1.01	ns
Marburg marburgvirus	0.44	0.98	ns
Puumala virus	0.41	1.58	ns
Mumps virus	0.40	4.13	ns
Human picobirnavirus	0.39	0.87	ns
Japanese encephalitis virus	0.38	0.82	ns
Alphapapillomavirus 5	0.37	2.44	ns
Simian virus 40 (SV40)	0.35	3.56	ns
Rotavirus B	0.34	1.28	ns
WU Polyomavirus	0.32	0.68	ns
Human parechovirus	0.32	0.22	*
Vesicular stomatitis Indiana virus	0.32	3.19	ns
JC polyomavirus	0.29	1.05	ns
Alphapapillomavirus 1	0.29	1.36	ns
Crimean-Congo hemorrhagic fever virus	0.27	1.75	ns
Monkeypox virus	0.25	0.90	ns
Human parainfluenza virus 2	0.25	1.63	ns
California encephalitis virus	0.19	Inf	ns
Human erythrovirus V9	0.17	0.41	ns
Junin virus	0.15	3.00	ns
Mupapillomavirus 2	0.15	0.88	ns

**Table S4. Viral species included in the analysis of phage immunoprecipitation sequencing (PhIP-seq)-based human virome-wide serological profiling (VirScan).** Average of summed epitope hits per species and the ratio of mean summed hits comparing COVID-19 patients (n = 97) and healthy individuals (n = 18) are indicated. P-values were calculated using Mann-Whitney U test. ns, non-significant; \*, p < 0.05; \*\*, p < 0.01; \*\*\*, p < 0.001; \*\*\*\*, p < 0.0001.

Variable name	Description	Method	Mean fold change ANA-pos / ANA-neg	p-value
Age		History	1.27	****
Days	Days after symptom onset	History	1.22	ns
IL-8	Interleukin 8	Olink	1.09	ns
VEGFA	Vascular epithelial growth factor A	Olink	1.03	***
CD8A	CD8α	Olink	1.05	ns
MCP3	Monocyte chemotactic protein 3	Olink	1.16	ns
GDNF	Glial cell line-derived neurotrophic factor	Olink	1.03	*
CDCP1	CUB domain-containing protein 1	Olink	1.34	***
CD244	Natural killer cell receptor 2B4	Olink	0.98	ns
IL-7	Interleukin-7	Olink	1.02	ns
OPG	Osteoprotegerin	Olink	1.02	***
LAP_TGFbeta1	Latency-associated peptide transforming growth factor β-1	Olink	1.03	*
uPA	Urokinase-type plasminogen activator	Olink	1.00	ns
IL-6	Interleukin-6	Olink	1.23	***
IL-17C	Interleukin-17C	Olink	1.10	*
MCP1	Monocyte chemotactic protein 1	Olink	1.02	ns
IL-17A	Interleukin-17A	Olink	0.93	ns
CXCL11	C-X-C motif chemokine 11	Olink	1.04	ns
AXIN1	Axin-1	Olink	1.03	ns
TRAIL	TNF-related apoptosis-inducing ligand	Olink	0.99	ns
IL-20Rα	IL-20 receptor subunit α	Olink	0.96	ns
CXCL9	C-X-C motif chemokine 9	Olink	1.10	****
CST5	Cystatin D	Olink	1.02	ns
IL-2Rβ	IL-2 receptor subunit β	Olink	1.01	ns
OSM	Oncostatin-M	Olink	1.05	ns
CXCL1	C-X-C motif chemokine 1	Olink	1.03	*
TSLP	Thymic stromal lymphoprotein	Olink	1.09	ns
CCL4	C-C motif chemokine 4	Olink	1.04	ns
CD6	CD6	Olink	1.00	ns
SCF	Stem cell factor	Olink	0.98	ns
IL-18	Interleukin-18	Olink	1.03	*
SLAMF1	Signaling lymphocytic activation molecule 1	Olink	1.17	****
TGFalpha	Transforming growth factor α	Olink	1.07	ns
MCP4	Monocyte chemotactic protein 4	Olink	1.02	*
CCL11	C-C motif chemokine 11	Olink	1.04	*
TNFSF14	TNF ligand superfamily member 14	Olink	1.02	ns
FGF23	Fibroblast growth factor 23	Olink	1.15	ns
IL-10Rα	IL-10 receptor subunit α	Olink	0.88	ns
FGF5	Fibroblast growth factor 5	Olink	1.13	*
MMP1	Matrix metalloprotease 1	Olink	1.03	ns
LIF_R	Leukemia inhibitory factor receptor	Olink	0.99	ns
FGF21	Fibroblast growth factor 21	Olink	1.07	ns
CCL19	C-C motif chemokine 19	Olink	1.03	ns
IL-15Rα	IL-15 receptor subunit α	Olink	1.25	***
IL-10Rβ	IL-10 receptor subunit α	Olink	1.05	ns
IL-18R1	IL-18 receptor 1	Olink	1.00	ns
PD_L1	Programmed cell death 1 ligand 1	Olink	1.00	ns
CXCL5	C-X-C motif chemokine 5	Olink	1.04	ns
TRANCE	TNF related activation-induced cytokine	Olink	0.99	ns
HGF	Hepatocyte growth factor	Olink	1.09	***
IL-12β	Interleukin-12 subunit β	Olink	1.10	ns
IL-24	Interleukin-24	Olink	1.21	ns
IL-13	Interleukin-13	Olink	1.31	*
MMP10	Matrix metalloprotease 10	Olink	1.02	ns
IL-10	Interleukin-10	Olink	1.01	ns
TNF	Tumor necrosis factor	Olink	1.08	*
CCL23	C-C motif chemokine 23	Olink	1.02	ns
CD5	CD5	Olink	1.03	ns
CCL3	C-C motif chemokine 3	Olink	1.08	*
Flt3L	Fms-related tyrosine kinase 3 ligand	Olink	1.00	ns

CXCL6	C-X-C motif chemokine 6	Olink	1.02	ns
CXCL10	C-X-C motif chemokine 10	Olink	0.99	ns
E4_BP1	Eukaryotic translation initiation factor 4E-binding protein 1	Olink	1.06	*
IL-20	Interleukin-20	Olink	0.97	ns
SIRT2	SIR2-like protein 2	Olink	1.03	ns
CCL28	C-C motif chemokine 28	Olink	1.13	***
DNER	Delta and Notch-like epidermal growth factor-related receptor	Olink	0.98	*
EN_RAGE	Prtoein S100-A12	Olink	1.03	ns
CD40	CD40L receptor	Olink	1.03	*
IFNgamma	Interferon- $\gamma$	Olink	0.94	ns
FGF19	Fibroblast growth factor 19	Olink	0.99	ns
IL-4	Interleukin-4	Olink	0.42	ns
LIF	Leukemia inhibitory factor	Olink	1.35	*
NRTN	Neurturin	Olink	0.93	ns
MCP2	Monocyte chemotactic protein 2	Olink	0.98	ns
CASP8	Caspase-8	Olink	1.00	ns
CCL25	C-C motif chemokine 25	Olink	1.03	ns
CX3CL1	Fractalkine	Olink	1.02	ns
TNFRSF9	TNF receptor superfamily member 9	Olink	1.08	***
NT3	Neurotrophin-3	Olink	1.01	ns
TWEAK	TNF superfamily memebr 12	Olink	1.02	ns
CCL20	C-C motif chemokine 20	Olink	1.06	ns
ST1A1	Sulfotransferase 1A1	Olink	0.97	ns
STAMBP	STAM-binding protein	Olink	0.98	ns
IL-5	Interleukin-5	Olink	0.96	ns
ADA	Adenosin deaminase	Olink	0.97	ns
TNFB	Tumor necrosis factor $\beta$	Olink	0.98	ns
CSF1	Macrophage colony-stimulating factor 1	Olink	1.01	*
S1-IgA	S1-specific IgA	ELISA	2.12	****
S1-IgG	S1-specific IgG	ELISA	2.07	***
IgG	IgG	ELISA	1.06	ns
IgG1	IgG1	ELISA	1.08	ns
IgG2	IgG2	ELISA	0.99	ns
IgG3	IgG3	ELISA	1.02	ns
IgG4	IgG4	ELISA	0.79	ns
IgM	IgM	ELISA	0.92	ns
IgA	IgA	ELISA	1.21	****
IgD	IgD	ELISA	1.10	ns
IgE	IgE	ELISA	1.11	ns
IL-1 $\beta$	Interleukin-1 $\beta$	ELISA	8.40	ns
IL-2	Interleukin-2	ELISA	2.27	ns
sIL-2R $\alpha$	Soluble IL-2 receptor subunit $\alpha$	ELISA	1.32	***
IL-5	Interleukin-5	ELISA	1.45	ns
IL-6	Interlukin-6	ELISA	1.87	***
IL-10	Interluekin-10	ELISA	0.68	ns
IL-12	Interleukin-12	ELISA	0.62	ns
IFN- $\gamma$	Interferon- $\gamma$	ELISA	0.74	ns
TNF- $\alpha$	Tumor necrosis factor $\alpha$	ELISA	1.32	ns
Lymphocytes	Count / $\mu$ l	FACS	1.17	ns
NK cells	Count / $\mu$ l	FACS	0.80	*
CD56 <sup>bright</sup> NK cells	Count / $\mu$ l	FACS	0.78	ns
CD56 <sup>dim</sup> NK cells	Count / $\mu$ l	FACS	0.79	ns
T cells	Count / $\mu$ l	FACS	0.92	ns
CD4 $^+$ T cells	Count / $\mu$ l	FACS	0.93	ns
CD8 $^+$ T cells	Count / $\mu$ l	FACS	0.90	ns
CD38 $^+$ CD4 $^+$ T cells	Count / $\mu$ l	FACS	0.77	ns
HLA-DR $^+$ CD4 $^+$ T cells	Count / $\mu$ l	FACS	1.01	*
HLA-DR $^+$ CD38 $^+$ CD4 $^+$ T cells	Count / $\mu$ l	FACS	1.43	ns
HLA-DR $^+$ CD38 $^+$ CD8 $^+$ T cells	Count / $\mu$ l	FACS	0.87	ns
CD38 $^+$ CD8 $^+$ T cells	Count / $\mu$ l	FACS	1.10	ns
HLA-DR $^+$ CD8 $^+$ T cells	Count / $\mu$ l	FACS	1.26	ns
CD19 $^+$ B cells	Count / $\mu$ l	FACS	3.42	ns
CD20 $^+$ B cells	Count / $\mu$ l	FACS	1.65	ns

Transitional B cells	Count / $\mu$ l	FACS	0.89	ns
Naive B cells	Count / $\mu$ l	FACS	1.13	ns
Memory B cells	Count / $\mu$ l	FACS	3.60	ns
IgD <sup>+</sup> memory B cells	Count / $\mu$ l	FACS	1.97	ns
IgD <sup>-</sup> memory B cells	Count / $\mu$ l	FACS	4.37	ns
Plasmablasts	Count / $\mu$ l	FACS	0.86	ns
CD21 <sup>low</sup> B cells	Count / $\mu$ l	FACS	32.20	ns

**Table S5. Variables included in principal component analysis (PCA) in Fig. 6A-B and Fig. S4A-B.** Shown are variables with ratio of means comparing ANA-positive and ANA-negative COVID-19 patients during acute infection (n = 146). P-values were calculated using Mann-Whitney U test. ns, non-significant; \*, p < 0.05; \*\*, p < 0.01; \*\*\*, p < 0.001; \*\*\*\*, p < 0.0001.

Variable name	Description	Method	Mean fold change ANA-pos / ANA-neg	p-value
Lymphocytes	Count / $\mu$ l	FACS	0.93	ns
NK cells	Count / $\mu$ l	FACS	0.90	ns
CD56 <sup>bright</sup> NK cells	Count / $\mu$ l	FACS	0.87	ns
CD56 <sup>dim</sup> NK cells	Count / $\mu$ l	FACS	0.90	ns
T cells	Count / $\mu$ l	FACS	0.93	ns
CD4 <sup>+</sup> T cells	Count / $\mu$ l	FACS	0.97	ns
CD8 <sup>+</sup> T cells	Count / $\mu$ l	FACS	0.92	ns
CD38 <sup>+</sup> CD4 <sup>+</sup> T cells	Count / $\mu$ l	FACS	0.78	*
HLA-DR <sup>+</sup> CD4 <sup>+</sup> T cells	Count / $\mu$ l	FACS	1.11	ns
HLA-DR <sup>+</sup> CD4 <sup>+</sup> T cells	Count / $\mu$ l	FACS	1.10	ns
CD38 <sup>+</sup> CD8 <sup>+</sup> T cells	Count / $\mu$ l	FACS	0.92	ns
HLA-DR <sup>+</sup> CD8 <sup>+</sup> T cells	Count / $\mu$ l	FACS	1.04	ns
CD38 <sup>+</sup> CD8 <sup>+</sup> T cells	Count / $\mu$ l	FACS	1.02	ns
CD19 <sup>+</sup> B cells	Count / $\mu$ l	FACS	0.97	ns
CD20 <sup>+</sup> B cells	Count / $\mu$ l	FACS	0.97	ns
Transitional B cells	Count / $\mu$ l	FACS	1.28	ns
Naive B cells	Count / $\mu$ l	FACS	1.09	ns
IgD <sup>+</sup> memory B cells	Count / $\mu$ l	FACS	0.74	***
IgD <sup>-</sup> memory B cells	Count / $\mu$ l	FACS	0.76	*
Plasmablasts	Count / $\mu$ l	FACS	0.71	ns
CD21 <sup>low</sup> B cells	Count / $\mu$ l	FACS	0.78	ns
Memory B cells	Count / $\mu$ l	FACS	0.75	*
SIgA	S1-specific IgA	ELISA	1.95	***
SIgG	S1-specific IgG	ELISA	1.78	****
IgG	IgG	ELISA	1.06	ns
IgG1	IgG1	ELISA	1.12	*
IgG2	IgG2	ELISA	0.96	ns
IgG3	IgG3	ELISA	1.10	ns
IgG4	IgG4	ELISA	1.00	ns
IgM	IgM	ELISA	0.73	***
IgA	IgA	ELISA	1.19	*
IgD	IgD	ELISA	1.51	ns
IgE	IgE	ELISA	1.24	ns
IL-1 $\beta$	Interleukin- $\beta$	ELISA	1.65	ns
IL-2	Interleukin-2	ELISA	0.70	ns
sIL-2R $\alpha$	Soluble IL-2 receptor subunit $\alpha$	ELISA	1.16	*
IL-5	Interleukin-5	ELISA	1.05	ns
IL-6	Interleukin-6	ELISA	2.28	*
IL-10	Interleukin-10	ELISA	1.44	***
IL-12	Interleukin-12	ELISA	0.76	ns
IFN- $\gamma$	Interferon- $\gamma$	ELISA	0.80	ns
TNF- $\alpha$	Tumor necrosis factor $\alpha$	ELISA	1.32	***
Age		History	1.49	****

**Table S6. Variables included in principal component analysis (PCA) in Fig. 6F-G.** Shown are variables with ratio of means comparing ANA-positive and ANA-negative COVID-19 patients six months after recovery (n = 107). P-values were calculated using Mann-Whitney U test. ns, non-significant; \*, p < 0.05; \*\*, p < 0.01; \*\*\*, p < 0.001; \*\*\*\*, p < 0.0001.

<b>Marker</b>	<b>Fluorophore</b>	<b>Manufacturer</b>	<b>Clone</b>
IgD	FITC	Beckman Coulter	IA6-2
CD21	PE	Beckman Coulter	BL13
CD19	ECD	Beckman Coulter	J3-119
CD27	PE-Cy7	Beckman Coulter	1A4CD27
CD24	APC	Beckman Coulter	ALB9
CD38	APC-Alexa Fluor 750	Beckman Coulter	LS198-4-3
IgM	Pacific Blue	Beckman Coulter	SA-DA4
CD45	Krome Orange	Beckman Coulter	J33
CD16	FITC	Beckman Coulter	3G8
CD56	PE	Beckman Coulter	N901
CD14	PE-Cy7	Beckman Coulter	RMO52
CD4	APC	Beckman Coulter	13B8.2
CD8	Alexa Fluor 700	Beckman Coulter	B9.11
CD3	APC-Alexa Fluor 750	Beckman Coulter	UCHT-1
CD45	PE-Cy7	Beckman Coulter	J33
CD3	ECD	Beckman Coulter	UCHT-1
CD4	FITC	Beckman Coulter	13B8.2
HLA-DR	PE	Beckman Coulter	Immu-357
CD38	PE-Cy5.5	Beckman Coulter	LS198-4-3

**Table S7: Antibody panel for quantification of major lymphocyte subsets by flow cytometry.**